Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Portfolio Pulse from
Merck has secured an exclusive global license to develop, manufacture, and commercialize LM-299, an investigational anti-PD-1/VEGF bispecific antibody from LaNova Medicines Ltd. This move strengthens Merck's oncology pipeline.
November 14, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck has entered into an exclusive global license agreement with LaNova Medicines to develop and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody, enhancing its oncology pipeline.
The acquisition of the global license for LM-299 is a strategic move by Merck to strengthen its oncology pipeline. This could lead to potential future revenue streams if the drug proves successful in clinical trials and commercialization.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90